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ABSTRACT
Aims: The objective was to evaluate whether sodium intake, assessed with the gold standard
24-h urinary collections, was related to long-term incidence of death, cardiovascular disease
(CVD) and diabetes mellitus (DM).
Methods: A cohort of 4630 individuals aged 25–64 years collected 24-h urine samples in
1979–2002 and were followed up to 14 years for the incidence of any CVD, coronary heart dis-
ease (CHD), stroke, heart failure (HF) and DM event, and death. Cox proportional hazards models
were used to estimate the association between the baseline salt intake and incident events and
adjusted for baseline age, body mass index, serum cholesterol, prevalent DM, and stratified by
sex and cohort baseline year.
Results: During the follow-up, we observed 423 deaths, 424 CVD events (288 CHD events, 142
strokes, 139 HF events) and 161DM events. Compared with the highest quartile of salt intake,
persons in the lowest quartile had a lower incidence of CVD (hazard ratio [HR] 0.70; 95% confi-
dence interval [CI], 0.51–0.95, p¼ .02), CHD (HR 0.63 [95% CI 0.42–0.94], p¼ .02) and DM (HR
0.52 [95% CI 0.31–0.87], p¼ .01). The results were non-significant for mortality, HF, and stroke.
Conclusion: High sodium intake is associated with an increased incidence of CVD and DM.
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Compared with the individuals with the highest salt
intake, persons with the lowest had 1.5 times lower
incidence of cardiovascular disease (CVD) and coronary
heart disease, and almost twice the lower incidence of
diabetes mellitus.
Introduction
The association between high sodium intake and ele-
vated blood pressure (BP) has been established in
numerous studies [1]. However, the role of excess
sodium as a risk factor for cardiometabolic disease,
and particularly what may be the optimal amount of
sodium intake, remain debated. In addition, the associ-
ation between sodium intake and risk of certain health
outcomes such as heart failure (HF) and diabetes mel-
litus (DM) have been scarcely studied.
Several prior adequately sized studies [2–4] on the
association between salt intake and incident cardiome-
tabolic disease have relied on sodium intake estimates
derived from spot urine samples. Spot urine samples
are less difficult to collect when conducting popula-
tion studies, but single, or preferably even multiple
24-h urine collections are regarded as the gold stand-
ard for assessing habitual sodium intake [5]. Spot urine
samples tend to overestimate sodium intake in the
low end, underestimate it in the high end, are suscep-
tible to systematic error, and are not recommended
by The International Consortium for Quality Research
on Dietary Sodium [6]. Many studies have demon-
strated a direct association between 24-h urine
sodium excretion and adverse health outcomes [6–9].
Studies using inaccurate methods such as spot or
overnight urine collections have, however, presented
no significant associations, an inverse association
between sodium excretion and mortality, or a direct
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association with coronary heart disease (CHD) in
women only [1–3].
Due to the conflicting results and limitations of
many earlier studies, the association between sodium
intake and the risk of cardiometabolic diseases
requires further elucidation. Therefore, we carried out
a comprehensive study aiming at assessing in a large,
randomly selected population sample whether sodium
intake, properly assessed with 24-h urinary collections,
was associated with the incidence of death, CVD




Finland is a unique country where sodium intake
using 24-h urinary excretion at the population level
has been systematically assessed in several successive
surveys since 1979. The present study used data from
up to 8990 participants of these population-based
samples comprising people aged 25–64 years at base-
line who participated in the North Karelia Salt Project
in 1979 [7], WHO FINMONICAstudiesin1982, 1987 or
the National FINRISK Study in 2002 [8] and provided a
24-h urinary collection.
The North Karelia Project was a pioneering lifestyle
study in a Finnish county with very high cardiovascu-
lar mortality and morbidity. The Salt project was a
substudy of this. In the baseline survey of the North
Karelia Salt Project in 1979, a random sample of 2487
individuals were drawn from the National Population
Register who were invited to fill in a lifestyle question-
naire and attend a physical examination. Those attend-
ing the physical examination were instructed to
provide a 24-h urinary collection. In total, 1593 partici-
pants provided complete data with 24-h urine collec-
tions. We excluded individuals reporting incomplete
collection and those aged 14–24 years to consider a
common age range for all cohorts (Supplementary
Figure S1).
The FINMONICA and FINRISK comprise a series of
population surveys organised by the Finnish Institute
for Health and Welfare that have been carried out
every 5 years since 1982 in four different geographical
regions of Finland. We considered participants of the
1982 and 1987 FINMONICA studies and the 2002
FINRISK Study (all these survey cohorts are later on
called as the FINRISK surveys) [10]. For each of these
surveys, a sample stratified by sex and 10-year age
group from the population aged 25–64 years were ran-
domly drawn from the national population register
and invited to take part in the study. The participants
filled in a lifestyle questionnaire following the
extended WHO MONICA protocol [9] and underwent
physical examination, including blood sampling,
anthropometric and BP measurements. At each study,
randomly chosen sub-sample of the participants were
also asked to collect a 24-h urine specimen
(Supplementary Figure S1). A total of 1382, 1151, and
909 individuals provided complete 24-h urine collec-
tions in 1982, 1987, and 2002, respectively.
A flow chart of the sample selection is provided in
the Supplementary Figure S1. We excluded duplicate
participations (n¼ 29, the earlier was excluded), indi-
viduals with missing data (n¼ 16), and individuals
aged <25 years (n¼ 236) resulting in 4632 individuals
included in the present analyses (Supplementary
Figure S1). Patients with prevalent CVD (n¼ 115), CHD
(n¼ 70), DM (n¼ 79), and HF (n¼ 29) at baseline were
excluded from the analyses related to each corre-
sponding outcome (Supplementary Figure S1).
All participants gave informed consent for their
data to be used in scientific research purposes with
anonymity. The Finnish Ethics committee has
approved the study protocol and this study complies
with the Declaration of Helsinki.
We adhered to the STROBE protocol (Strengthening
the Reporting of Observational Studies in
Epidemiology) [11] for reporting observational studies.
Covariates
At the baseline examinations, systolic and diastolic BP,
height and weight were measured by a nurse trained
for the survey methods. Blood samples were drawn
after a minimum of 4-h fast for the determination of
serum lipids. BMI was defined as weight (kg) divided
by height (m) squared. Smoking was defined as self-
reported daily use of tobacco products during the last
six months (data not available for the 1979 survey).
Prevalent DM was defined as a register-based diagno-
sis of DM before baseline using the same criteria as
for incident DM (see Follow-up and outcomes). A 24-h
urine collection was performed to assess urinary
sodium, potassium and creatinine excretion. The col-
lection day was Sunday in most cases. The participants
were not informed about the purposes of the urine
collection in order to avoid bias from reducing salt
intake before the urine collection. People who
reported an incomplete 24-h collection or with urine
volumes less than 1000ml were excluded. According
to an external quality assurance programme organised
by Lab quality (Helsinki, Finland), the bias of the
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sodium assay method was 1.4% (SD 0.55, n¼ 12) in
1979, 4.0% (SD 2.08, n¼ 10) in 1982, 1.9% (SD 1.81,
n¼ 10) in 1987 when measurements were performed
using a flame photometer, and decreased to 0.2% (SD
1.85, n¼ 12) in 2002, when an ion-selective electrode
was used. Details of the urine collections have been
described earlier [12].
Follow-up and outcomes
The primary outcomes in our study were death, and
incidence of CVD, CHD, HF, stroke, and DM. The partic-
ipants were followed up through the National Causes
of Death Register (CDR), the Finnish Hospital
Discharge Register (FHDR) [10] and the Drug
Reimbursement Register for up to 14 years after the
baseline assessment.
The CHD event was defined as the International
Classification of Diseases 10th edition (ICD-10, Finnish
version) codes I20-I22 and ICD-8/9 codes 410 or 4110
in the FHDR for nonfatal cases; or as the ICD-10 codes
I20-I25, I46, R96, R98 or the ICD-8/9 codes 410-414 in
the CDR for fatal ones.
HF was defined as the ICD-10 codes I50, I110, I130,
I132 or the ICD9 codes 4029B, 4148, and 428, or the
ICD-8 codes 42700, 42710 and 428 in the FHDR.
Stroke was defined as the ICD-10-codes I61 and
I63-64 (but not I636, excluding subarachnoid haemor-
rhages and venous occlusions, but including intracere-
bral haemorrhages) or the ICD-9 codes 430-314,330A,
4331A, 4339A, 4340A, 4341A, 4349A, and 436, or the
ICD-8 codes 431 (except 43101, 43191) 433, 434, 436.
DM was defined as the ICD-10 codes E10-E14 or
the ICD-8/9 code 250 in the FHDR or CDR. Because
ICD-8 only had one code for diabetes, we, too, were
forced to combine the subtypes of DM.
CVD was defined as the onset of CHD, stroke,
or HF.
The FHDR and CDR have been validated for diagno-
ses of CHD, myocardial infarction, stroke and HF and
shown to provide accurate diagnostic informa-
tion [10,13–15].
Statistical methods
We divided the participants into quartiles according to
their 24-h urinary sodium excretion. The characteristics
of the study sample by sodium excretion quartiles
were compared using ANOVA with equal variance
assumption for continuous variables and chi-squared
tests with continuity correction for categorical varia-
bles. Cox proportional hazards models were used to
estimate the risk of adverse health outcomes at differ-
ent levels of sodium excretion. The proportional haz-
ards assumption of the models was tested using
Schoenfeld residuals. The fourth (highest) quartile had
the largest number of events and was used as the ref-
erence category in all analyses to maximise statistical
power. We also used restricted cubic splines with four
knots to model the continuous, non-linear association
between urinary sodium excretion and adverse health
outcomes. For these analyses the median sodium
excretion (170.6mmol/day, corresponding to 10.0 g
NaCl/day) was used as the reference level with hazard
ratio 1.0, bypassing the categorical quartiles. We
included age, survey year, sex, serum total cholesterol,
prevalent DM and BMI as covariates in analyses for
mortality and CVD events, and age, survey year, sex,
Table 1. Characteristics by quartiles of 24-hour urinary sodium excretion.
Characteristic
Quartile of urinary sodium excretion
Total p Value
Q1 Q2 Q3 Q4
N 1157 1159 1158 1158 4632
Age, years 45.4 (11.7) 45.4 (11.5) 45.4 (11.4) 45.5 (10.8) 45.4 (11.4) .99
Women, n (%) 812 (70.2) 703 (60.7) 548 (47.3) 324 (28.0) 2387 (51.5) <.001
Body mass index, kg/m2 25.2 (4.1) 25.8 (4.1) 26.7 (4.2) 27.9 (4.4) 26.4 (4.3) <.001
Total cholesterol, mmol/l 5.9 (1.3) 6.0 (1.2) 6.2 (1.3) 6.4 (1.3) 6.1 (1.3) <.001
Systolic BP, mmHg 138 (21) 139 (20) 142 (21) 145 (20) 141 (21) <.001
24-h urinary Na
Range, mmol/day 12–127 127–171 171–224 225–685 12–685 <.001
Mean, mmol/day 97.1 (21.9) 149.0 (12.8) 196.6 (15.6) 289.5 (61.4) 183.1 (78.6) <.001
Estimated 24-h salt (NaCl) intake
Range, g/day 0.7–7.4 7.4–10.0 10.0–13.1 13.1–40.0 0.7–40.0 <.001
Mean, g/day 5.7 (1.3) 7.9 (0.61) 10.0 (0.6) 12.5 (0.8) 10.7 (4.6) <.001
Examination year, n (%)
1979 212 (18.3) 266 (23.0) 342 (29.5) 410 (35.4) 1230 (26.6) <.001
1982 260 (22.5) 319 (27.5) 380 (32.8) 389 (33.6) 1348 (29.1) <.001
1987 258 (22.3) 328 (28.3) 289 (25.0) 274 (23.7) 1149 (24.8) <.001
2002 427 (36.9) 246 (21.2) 147 (12.7) 85 (7.3) 905 (19.5) <.001
Data are presented as mean (SD) unless indicated otherwise. p Values for continuous variables are from regular ANOVA with equal variance assumption
and for categorical variables from chi-squared tests with continuity correction. One gram of salt intake is calculated as equal of 17.1mmol sodium excre-
tion. BP: blood pressure; SD: standard deviation.
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serum total cholesterol and BMI as covariates for the
DM analyses. All analyses were stratified by age and
survey cohort year, i.e., a separate hazard function was
estimated for each combination of sex and cohort in
the statistical model. We included systolic BP as a
covariate only in a sensitivity analysis to avoid over-
adjustment bias, i.e. controlling for an intermediate
variable on a causal path from exposure to outcome.
In addition, we included smoking as a covariate for
the 1801 participants of the 1982, 1987 and 2002
cohorts with data available in a separate analysis. The
effect of cohort was also studied in a separate sub-
group analysis. All analyses were performed using
R v.3.5.1.
Results
Selected characteristics of the study sample are pre-
sented in Table 1. The mean age at baseline was
45.4 years and 51.5% were women. The proportion of
women decreased, while BMI, serum total cholesterol,
and systolic BP increased with the increasing quartiles
of sodium excretion. The mean sodium excretion was
183mmol/day (corresponding to 10.7 g NaCl/day),
decreasing with the successive survey cohort years
(Table 1).
The individuals were followed for death for a
median time period of 14.0 years accumulating 62 402
person years. During this time frame, we observed 423
deaths, 424 CVD events, 288 CHD events, and 142
strokes. In addition, 142 individuals developed DM
and 139 HF (Table 2). The proportion of individuals
experiencing adverse health events increased across
the increasing sodium excretion quartiles, except for
stroke where the nadir was seen in the second lowest
quartile (Table 2).
Outcome-free survival is depicted in Figure 1with
Kaplan–Meier curves. The number of censored individ-
uals and those remaining at risk at any given time are
reported in Supplementary Table S1. The unadjusted
and adjusted risks of incident adverse health events in
the quartiles of sodium excretion are presented in
Supplementary Figure S2 and Figure 2. In the
unadjusted models (Supplementary Figure S2), the risk
of adverse health events was always the lowest in the
first quartile of sodium excretion, except for stroke.
The stroke incidence in the second quartile of sodium
excretion was significantly lower than in the highest
(fourth) quartile. In the multivariable-adjusted models,
we observed significantly lower risks for CVD, CHD
and DM in the lowest quartile of sodium excretion
compared with the highest quartile (Figure 2).
The unadjusted analyses of the continuous associ-
ation between sodium excretion and the risk of
adverse health outcomes are shown in Supplementary
Figure S3; the risk of all adverse health outcomes
increased with the increasing level of sodium excre-
tion. However, the adjustment for covariates markedly
attenuated these associations (Figure 3); only the risk
of CVD, stroke and DM significantly increased with
increasing sodium excretion, with a borderline
increase in mortality. For stroke, the observed numer-
ical increase of risk at the lower levels of sodium
excretion was not statistically significant in the
adjusted or unadjusted analyses.
We also performed a sensitivity analysis including
smoking as a covariate in the 1801 individuals with
smoking data available (Supplementary Figure S4). The
results remained essentially unchanged but became
somewhat stronger for DM and HF and attenuated the
shape of the curve in the stroke analysis. The associa-
tions were similar when the cohorts were analysed
separately and also when systolic BP was included as
a covariate in the models (Supplementary Figures S5
and S6).
Discussion
This study was carried out to elucidate whether
sodium intake, measured with a single 24-hour base-
line urinary collection, is associated with an increased
risk of mortality and cardiometabolic adverse events
during the longest follow-up thus far. We found a dir-
ect association between the 24-hour urinary sodium
Table 2. Number of incident adverse outcomes by quartiles
of 24-h urinary sodium excretion.
Outcome
Quartile of urinary sodium excretion
Total p value
Q1 Q2 Q3 Q4
Mortality
N 1157 1159 1158 1158 4632
No. overall deaths 79 (6.8) 95 (8.2) 104 (9.0) 145 (12.5) 423 (9.1) <.001
Cardiovascular disease
N 1141 1131 1126 1119 4517
No. events 72 (6.3) 84 (7.4) 105 (9.3) 163 (14.6) 424 (9.4) <.001
Coronary heart disease
N 1151 1140 1137 1134 4562
No. events 39 (3.4) 64 (5.6) 74 (6.5) 111 (9.8) 288 (6.3) <.001
Stroke
N 1150 1152 1154 1153 4609
No. events 35 (3.0) 19 (1.6) 33 (2.9) 55 (4.8) 142 (3.1) .004
Diabetes mellitus
N 1145 1145 1134 1129 4553
No. events 24 (2.1) 26 (2.3) 45 (4.0) 66 (5.8) 161 (3.5) <.001
Heart failure
N 1153 1157 1149 1144 4603
No. events 23 (2.0) 31 (2.7) 34 (3.0) 51 (4.5) 139 (3.0) .040
Data are presented as n (%). Individuals with a prevalent disease have
been removed from the corresponding analyses. Cardiovascular disease
event includes composite outcomes of coronary heart disease, stroke and
heart failure. p Values are for chi-squared tests.
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excretion and the incidence of CVD, CHD, stroke and
DM, but not with all-cause mortality and HF. The risk
of disease was lowest when sodium excretion was
between 120 and 150mmol/day, i.e. 7.0–8.8 grams of
salt per day. However, as some of the cohorts were
examined at a time when mean sodium intake in the
Finnish population was >10 g/day [12], we refrain
from making any strong recommendations on the
optimal level of salt intake for CVD prevention. Even
though CVD risk profiles have changed during the last
40 years due to changes in lifestyle and therapeutic
modalities, CVD risk increased in all cohorts with
increasing sodium excretion.
Several other cohort studies have been carried out
on the relation of 24-h or overnight sodium excretion
and cardiovascular mortality and morbidity (namely
CHD and stroke) in Scotland, Northern Belgium, the
Netherlands and the United States [16–19]. The
median follow-up time in these studies ranged from
3.8 to 7.9 years. Alderman et al. reported an inverse
relation with 24-h urinary sodium excretion at baseline
and a subsequent myocardial infarction in hyperten-
sive individuals in 1995 [19], which was strongly
criticised for bias [20]. The Scottish Heart Health Study
investigators observed a borderline inverse gradient
for mortality and urinary sodium excretion, and a dir-
ect gradient for CHD in women only [16]. An inverse
association of sodium excretion and CVD and mortal-
ity was surprisingly discovered in the Belgian study
[17]. The results from the Netherlands reported a
Figure 1. Outcome-free survival after baseline by quartiles of 24-h sodium excretion. Log rank P value for all outcomes < .001.
Numbers of censored events and individuals at risk at each time point are provided in Supplementary Table S1.
Figure 2. Multivariable-adjusted risk of adverse health outcomes by quartiles of 24-h urinary sodium excretion. Models are
adjusted for baseline age, body mass index, cholesterol, prevalent diabetes and stratified by sex and cohort. Individuals with a
prevalent disease in question at baseline have been removed from the corresponding analyses. CI: confidence interval; HR: haz-
ard ratio.
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direct association between urinary sodium excretion
and mortality [18]. Prior results from the National
FINRISK Study also showed a direct, statistically signifi-
cant association of 24-h urinary sodium for CVD mor-
bidity and mortality, particularly in men [21]. The
sample of this study consisted of approximately half
of the participants included also in our current study,
precisely 35 023 person years (56%) in contrast to 62
402 person years of follow-up in our current study. In
addition to observational data that are prone to bias,
some data also exist from intervention studies. In the
trial by Cook et al., a reduction in 24-h urinary sodium
excretion achieved by nutritional education and coun-
selling in the intervention group resulted in a 25%
lower CVD morbidity [22]. The findings on the direct
association of excess sodium excretion and CVD were
further supported also by a recent meta-analysis of
observational studies by Poggio et al. [23]. Our results
on the harmful effects of excess sodium intake on
CVD and CHD support the earlier findings from the
National FINRISK Study [21], the Scottish Heart Health
Study [16], and the interventional trial by Cook et al.
[22] Overnight urine collections have been shown to
underestimate 24-h values [24], a potential reason
why the Dutch study [18] investigators did not
observe a correlation between urinary sodium excre-
tion and CVD. There are also numerous potential rea-
sons for the contradictory, inverse associations
reported in the Belgian study and by Alderman
[17,19]. Individuals with CVD at baseline were not
excluded from the study by Alderman, leading to pos-
sible reverse causality when study participants at high-
est CVD risk may have been instructed to lower their
sodium intake. In addition, there was evidence of sys-
tematic errors in sodium assessment in both studies
and other limitations, also, which are described in
detail in the meta-analysis by Cobb et al. [20].
The association of excess sodium excretion meas-
ured by 24-h urine collections and the onset of type
2DM has been studied once by Hu et al. [25] using
part of the cohort included in our present study (1935
participants of the FINMONICA 1982 and 1987
cohorts). The investigators observed a multivariable-
adjusted hazard ratio of 2.05 in the highest vs. com-
bined lower quartiles of urinary sodium excretion and
type 2DM. Our present study extends and confirms
Figure 3. Multivariable-adjusted risk of adverse health outcomes by 24-h sodium excretion. Hazard ratios (black line) were esti-
mated using Cox proportional hazards regression and plotted by restricted cubic splines. The models are centered at the median
(dashed line, 170.6mmol/day; hazard ratio ¼ 1.0) with 4 knots at the 5th, 35th, 65th and 95th percentiles and the plot truncated
at the 2.5th and 97.5th percentiles. The grey lines represent the 95% confidence interval. The models are adjusted for baseline
age, body mass index, cholesterol, prevalent diabetes and stratified by sex and cohort. The density of the observations along the
spline variable is marked by the mountain plot, marking the median and the 1st and 3rd quartile with vertical lines.
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the findings of Hu et al. on the association between
sodium excretion and DM by having twice the sample
size, a longer follow-up, a wider sodium excretion
range, and including most incident cases of DM. The
exact underlying causes linking sodium excretion and
incident DM remain unclear, but currently available
processed foods almost without exception contain
high concentrations of sodium. Thus, it is possible that
sodium excretion in this case only acts as a proxy for
energy intake in some individuals thereby resulting in
risk of obesity, metabolic syndrome and type 2DM. In
addition, there is some evidence linking insulin resist-
ance and hypertension-related salt sensitivity in obese
individuals [26]. Although we adjusted our analyses for
BMI, which would account for much of this potential
collinearity, some residual confounding may
still remain.
To our knowledge, the association of excess sodium
intake and incident HF has not been studied before
using the 24-h urinary sodium excretion data. Using
spot urine samples and lifestyle questionnaires, the
EPIC-Norfolk study showed a statistically significant
increased risk of HF (hazard ratio 1.32 in the highest
quintile compared with the second lowest quintile) in
a study sample of 25,639 persons from the UK [27].
There was a marked attenuation of this association
(hazard ratio, 1.21; 95% confidence interval, 0.98–1.49)
after adjusting for hypertension, a major risk factor for
HF. This might have been an over-adjustment, since
high salt intake is a risk factor for hypertension; thus,
hypertension is not a confounding factor in
this respect.
An inverse relation with stroke and urinary sodium
excretion using multiple 24-h collections was reported
in an earlier study by Kieneker et al. [28]. On the con-
trary, another study reported that stroke patients who
had not reduced their salt intake previously were
more likely to suffer from a recurring lacunar stroke
[29]. Our study demonstrated a mild J-curve for the
association between salt excretion and stroke risk,
which was different from other CVD outcomes where
associations were increasing monotonously. However,
the increased risk of stroke in the lowest level of
sodium excretion was greatly attenuated in the sensi-
tivity analysis with smoking included as a covariate,
demonstrating the crucial role that smoking plays as a
risk factor for stroke. In addition, the J-shaped associ-
ation may attenuate when additional 24-h collections
taken at different time points are used for assessing
sodium intake [6].
In addition to difficulties with an accurate measure-
ment of sodium intake and study settings, sodium
metabolism is very convoluted. Many aspects of it still
remain elusive due to challenges related to variation
in dietary sodium intake and urinary sodium excretion,
and total body sodium content and its regulation [5].
These challenges could also contribute to the varying
results on the relation between sodium intake and
CVD outcomes in the previous studies. Measuring
body sodium homeostasis is relatively inaccurate as
sodium excretion has a wide day-to-day and within-
day variability and because sodium intake and excre-
tion are not in balance within a 24-h timeframe.
Furthermore, recent evidence suggests that total body
sodium is not regulated tightly within narrow limits
and sodium may be instead stored within the body
up to a certain limit [30]. Data obtained in the closed
environment of the Mars500 study [31] revealed a
fairly long infradian rhythmic of approximately six
days of the daily urinary excretion with considerable
day-to-day within-person variability even with a fixed
daily sodium intake. These findings together with the
previous results [24] suggest that possibly a single 24-
h urine collection, not to mention a spot urine sample,
is too inaccurate for assessing habitual sodium intake
of an individual. Unfortunately, 24-h urine collections
also have other limitations such as challenges related
to incomplete urine collections and variations in
sodium excretion caused by everyday life situations. In
addition, obtaining even single 24-h urine collections
is often burdensomefor the study participants.
In addition to difficulties in measuring body sodium
homeostasis, research on the effects of sodium on
health has numerous pitfalls. These limitations, such as
systematic error in sodium assessment, potential
reverse causality, inadequate adjustment for confound-
ers, imbalance across study groups, etc., are detailed
in the meta-analysis of prior studies on urinary sodium
and CVD outcomes by Cobb et al. [20]. We avoided
many of these limitations in our study; reverse causal-
ity was addressed by excluding individuals with rele-
vant prevalent disease conditions at baseline, we
adjusted for all relevant covariates, including age, BMI,
serum cholesterol, smoking and prevalent DM and
stratified the analyses by sex and cohort year, and per-
formed sensitivity analyses with additional covariates.
Individuals with self-reported incomplete urine collec-
tions were excluded from our analyses. However, sev-
eral limitations are still present. Assessing medication
or kidney function has not been part of the study
protocol and might affect the results. Regression dilu-
tion bias in sodium assessment may have remained in
our study as the participants provided only a single
24-h urine specimen. In addition, the sample collection
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day of Sunday might have had an effect on the mean
sodium levels due to differences between weekend
and weekday eating habits. However, the daily
amount of sodium consumed is reflected in urinary
sodium excretion mainly several days later [31] and
Sunday collections can be expected to mirror also
weekday sodium consumption to some extent.
Furthermore, we still expect the rank order of the par-
ticipants to remain mainly the same as it would have
been with a random collection day. Sunday was
chosen simply because it was the easiest day of the
week to collect urine for a large cohort of people, and
thus would result in more collections returned.
Furthermore, advances in medicine during the 30-
year-period that our study covers predispose the ear-
liest participants to cardiovascular conditions in a dif-
ferent manner than the participants in the more
recent surveys. During the study period there have
been some changes in diagnostic criteria for CVD and
DM, but these have not affected differentially people
at different levels of sodium intake at baseline. Also,
we don’t know the number of people with insulin-
deficient or type 1DM in the study because of a single
mutual code in ICD-8 , although statistically most of
our cases would have type 2DM. In addition, the
Hospital Discharge and Drug Reimbursement Registers
have not been validated for diabetes diagnoses.
However, since people with diabetes have had free-of-
charge glucose-lowering drug treatment once regis-
tered in the Drug Reimbursement Register, virtually all
diabetic patients have used this privilege.
Excess sodium intake at the population level is very
common. Identification of individuals who would
benefit most from avoiding excess sodium is regarded
as one of the crucial steps in reducing CVD morbidity
and mortality [23]. This study provides additional evi-
dence on the harmful health effects of excess sodium
intake in the general population.
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